MedTrace Logo

Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD

NCT00421122 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2009-03-27

No results posted yet for this study

Summary

This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD patients as defined by GOLD treatment guidelines in order to obtain an approval for indication of COPD from Chinese State Food and Drug Administration.

Conditions

Interventions

DRUG

budesonide/formoterol (Symbicort)

inhalation therapy

DRUG

budesonide (Pulmicort)

inhalation

DRUG

terbutaline sulfate (Bricasol)

inhalation therapy

Sponsors & Collaborators

Principal Investigators

  • Symbicort Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00421122 on ClinicalTrials.gov